Vertex Pharmaceuticals announced that the combination of its hepatitis C drug telaprevir with Roche Holding's Pegasys and Copegus eradicated signs of the virus and elicited sustained response in 52% of patients, compared with 14% of those who received Roche's medicines alone. The yearlong study observed 453 patients who either relapsed after or failed to respond to previous hepatitis C therapies.

Full Story:

Related Summaries